SUPN Q2 2020 Earnings — Supernus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SUPNSupernus Pharmaceuticals, Inc.

$3B

Q2 2020 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$127M+21.0% YoY

Gross Profit

$118M93.4% margin

Operating Income

$46M35.9% margin

Net Income

$35M27.4% margin

EPS (Diluted)

$0.65

QoQ Revenue Growth

+33.4%

Cash Flow

Operating Cash Flow

$92M

Free Cash Flow

$91M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$1.5B

Total Liabilities

$825M

Stockholders' Equity

$666M

Cash & Equivalents

$211M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$127M	$105M	+21.0%
Gross Profit	$118M	$101M	+17.6%
Operating Income	$46M	$43M	+6.9%
Net Income	$35M	$33M	+5.9%

Revenue Segments

Product

$124M49%

Trokendi Xr

$90M36%

Oxtellar X R

$24M9%

APOKYN

$9M3%

Royalty

$3M1%

MYOBLOC

$1M0%

XADAGO

$801,0000%